A multicenter trial of interleukin-2 and low-dose cyclophosphamide in highly chemotherapy-resistant malignancies.

Abstract

The anti-tumor activity of high-dose recombinant interleukin-2 (IL-2) has been demonstrated in several recent preclinical and clinical studies. In an attempt to study possible synergistic effects with low-dose cyclophosphamide (CYC), a phase II clinical trial was initiated in 32 patients, 18 with malignant melanoma (MM) and 14 with renal cell carcinoma (RCC). The recombinant IL-2 (Cetus Corp., Emeryville, Ca, U.S.A.) was given once daily at 3 x 10(6) U/m2, as a 30-min infusion for 14 days in cycle I and for five days twice in cycles II and III, respectively; if tolerated, the dose was escalated to a maximum of 6 x 10(6) U/m2/day; the cycles, separated by 1-week treatment-free intervals, were each preceded by a single i.v. bolus of CYC at 350 mg/m2. The most prominent side-effects encountered in this trial consisted of a capillary leak syndrome, myalgia and fever requiring dose reduction in half of the patients during the first cycle. Given the limit of tolerable toxicities in a standard care unit, the regimen employed achieved minor anti-tumor activity. No objective responses were achieved in patients with RCC and a 15% remission rate (PR + MR) was seen in melanoma patients.

Statistics

0200400'92'95'98'01'04'07'10'13'16
Citations per Year

324 Citations

Semantic Scholar estimates that this publication has 324 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Lindemann1989AMT, title={A multicenter trial of interleukin-2 and low-dose cyclophosphamide in highly chemotherapy-resistant malignancies.}, author={Albrecht Lindemann and Klaus Hoeffken and R. E. Schmidt and Volker Diehl and Otto Kloke and Heinhold Gamm and J{\"{o}rg Hayungs and W . Oster and Markus B{\"{o}hm and Chris R. Franks}, journal={Cancer treatment reviews}, year={1989}, volume={16 Suppl A}, pages={53-7} }